Using primary human immune cells to evaluate novel therapeutics.
Research type
Research Study
Full title
Research into immune cell function and human diseases in which the immune system plays a role. The effect of novel therapeutics will be evaluated in order to identify approaches that might be beneficial in treating disease.
IRAS ID
319914
Contact name
Rhiannon Jenkinson
Contact email
Sponsor organisation
Nexus BioQuest
Duration of Study in the UK
4 years, 11 months, 31 days
Research summary
In order to develop drugs to treat or prevent human disease a significant amount of scientific research needs to be done and a large proportion of this research is outsourced to contract research organisations. Nexus BioQuest is a pre-clinical contract research organisation that collaborates with Biotechnology and Pharmaceutical companies in order to help accelerate their research programmes. All of our work is built on our deep understanding of the immune response, allowing us to provide relevant, customisable, cutting-edge assays, to advance our partners' drug development programs. Collectively members of the company have significant experience working in the industry including the management and control of relevant human tissue.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
22/EE/0253
Date of REC Opinion
4 Nov 2022
REC opinion
Unfavourable Opinion